News

Lisata Therapeutics Announces Participation in Upcoming Conferences in May

BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

2 years ago

Press Release: Sanofi completes acquisition of Provention Bio, Inc.

Sanofi completes acquisition of Provention Bio, Inc. Paris, April 27 2023. Sanofi announced today the completion of its acquisition of…

2 years ago

Avenue Therapeutics to Present at Aegis Capital Virtual Conference

MIAMI, April 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company…

2 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

WILMINGTON, Del., April 27, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced…

2 years ago

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…

2 years ago

IRADIMED CORPORATION to Hold 2023 First Quarter Financial Results Conference Call on May 4th

WINTER SPRINGS, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its…

2 years ago

Angel Medical Systems, Creator of the Guardian™, First Implantable Cardiac Alert System, Changes Name to Avertix Medical Inc. and Welcomes New CEO and CFO to Drive Continued Growth and Success

New company name chosen to represent focus on ‘averting’ serious cardiac complications with state-of-the-art Guardian™ monitoring and alerting system President…

2 years ago

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial

Tel Aviv, Israel / Vancouver, Canada, April 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:…

2 years ago

Tavros Therapeutics and OpenBench Expand Strategic Collaboration for Small Molecule Drug Discovery

Multi-target collaboration leverages Tavros’ proprietary functional genomic discovery program and OpenBench’s screening platform Partnership streamlines drug development for novel cancer…

2 years ago

Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference

Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in…

2 years ago